Literature DB >> 18657863

Characterization of intracellular HLA-DR, DM and DO profile in K562 and HL-60 leukemic cells.

Lina Papadimitriou1, Ioannis Morianos, Valentina Michailidou, Eva Dionyssopoulou, Simon Vassiliadis, Irene Athanassakis.   

Abstract

Surface class-II antigen expression fires-up the antigen presentation process and development of immune response. The absence of surface HLA-DR is used in various systems to avoid immune recognition. Most leukemic cells use such mechanism to escape immune surveillance. Here, K562 and HL-60 leukemic cells were examined as to intracellular HLA-DR, -DM and -DO expression, if any. Immunofluorescence scored by UV-microscopy, flow cytometry or confocal microscope analysis detected intracellular pools of HLA-DR, -DO and to a lesser degree HLA-DM, whereas sub-cellular fractionation localized these molecules within endosomes. RT-PCR experiments revealed the presence of HLA-DRalphabeta, HLA-DMalphabeta and HLA-DObeta but not HLA-DOalpha transcripts. Despite the absence of the HLA-DOalpha chain, stable transfectants of K562 with a full length HLA-DObeta-EGFP construct showed that DObeta chain could be translocated to endosomes and form stable complexes with HLA-DR. Such complexes could be responsible for arresting HLA-DR molecules within endosomes, maintaining their surface class-II negative state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657863     DOI: 10.1016/j.molimm.2008.06.017

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.

Authors:  Marcus O Butler; Sascha Ansén; Makito Tanaka; Osamu Imataki; Alla Berezovskaya; Mary M Mooney; Genita Metzler; Matthew I Milstein; Lee M Nadler; Naoto Hirano
Journal:  Int Immunol       Date:  2010-11-08       Impact factor: 4.823

2.  Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.

Authors:  Fan Fei; Liang Rong; Nan Jiang; Alan S Wayne; Jianming Xie
Journal:  Mol Ther       Date:  2021-11-18       Impact factor: 11.454

Review 3.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Authors:  Harjeet Singh; Helen Huls; Partow Kebriaei; Laurence J N Cooper
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

4.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

Review 5.  What to do with HLA-DO/H-2O two decades later?

Authors:  Robin Welsh; Nianbin Song; Scheherazade Sadegh-Nasseri
Journal:  Immunogenetics       Date:  2019-01-26       Impact factor: 2.846

6.  Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens.

Authors:  Sandra Rosskopf; Sabrina Jutz; Alina Neunkirchner; Martín R Candia; Beatrice Jahn-Schmid; Barbara Bohle; Winfried F Pickl; Peter Steinberger
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01

8.  Lack of the MHC class II chaperone H2-O causes susceptibility to autoimmune diseases.

Authors:  Robin A Welsh; Nianbin Song; Catherine A Foss; Tatiana Boronina; Robert N Cole; Scheherazade Sadegh-Nasseri
Journal:  PLoS Biol       Date:  2020-02-18       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.